Menu

Rainy Season Likely to Exacerbate Yemen’s Cholera Outbreak

Pregnant and lactating women are particularly vulnerable to the disease.

Aug 18, 2017
Shawna Williams

ISTOCKThe World Health Organization (WHO) announced this week that the number of recent cholera cases in Yemen has surpassed 500,000, and nearly 2,000 people there have died from the disease since the outbreak began in April.

Although the infection has a 99 percent survival rate if properly treated, the country’s healthcare structure has been “decimated” by war, the United Nations has stated. “A collapsing health system is struggling to cope, with more than half of all health facilities closed due to damage, destruction or lack of funds. Shortages in medicines and supplies are persistent and widespread and 30,000 critical health workers have not been paid salaries in nearly a year,” WHO notes.

See “Cholera Ripping Through Yemen”

The United Nations Population Fund had previously reported that pregnant and lactating women, especially those who are malnourished, are particularly at risk from the diarrheal disease. Also vulnerable are children and the elderly.

Despite widespread lack of access to health care and clean water, Deputy Representative of Unicef to Yemen, Sherin Varkey, tells Gulf News that interventions have succeeded in slowing the infection rate. But, he added, the upcoming rainy system is likely to reverse that trend.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.